Paget's Disease of Bone: Treatment Recommendations
For symptomatic Paget's disease of bone, treat with a single 5 mg intravenous infusion of zoledronic acid, which is the most effective bisphosphonate and provides sustained suppression of bone turnover for years. 1, 2, 3
Diagnosis and Initial Assessment
Confirm diagnosis with plain radiographs of the affected skeletal regions showing characteristic features (mixed lytic-sclerotic lesions, bone expansion, cortical thickening). 2, 3
Obtain a radionuclide bone scan to fully define the extent of metabolically active disease throughout the skeleton, as Paget's can affect multiple sites not apparent on targeted radiographs. 2, 3
Measure serum total alkaline phosphatase (ALP) in combination with liver function tests as the first-line biochemical marker to assess disease activity. 2, 3 If ALP is normal but clinical suspicion remains high, consider more specific bone turnover markers like PINP (procollagen type 1 N-terminal propeptide) or CTX (C-telopeptide). 4, 3
Treatment Indications
Treat patients who have:
- Bone pain attributable to Paget's disease 2, 3
- Risk of future complications including involvement of weight-bearing bones, skull base (hearing loss risk), spine (neurologic compression risk), or bones adjacent to major joints (osteoarthritis risk) 3, 5
- Planned orthopedic surgery on pagetic bone 3
Do NOT routinely treat asymptomatic patients with the goal of normalizing ALP ("treat-to-target"), as bisphosphonates have been associated with increased fracture rates in asymptomatic Paget's disease. 6, 2
Specific Treatment Protocol
First-line therapy: Zoledronic acid 5 mg as a single intravenous infusion over 15-30 minutes. 1, 2, 4, 3
- This provides the most potent and sustained suppression of bone turnover, often normalizing biochemical markers for 2-6.5 years after a single dose. 4, 7
- Ensure adequate vitamin D status (≥30 ng/mL) and calcium intake before administration to prevent hypocalcemia. 3
- Pretreat with acetaminophen to reduce acute-phase reaction (fever, myalgias). 3
Alternative oral bisphosphonates (if IV zoledronic acid is contraindicated):
Note: Oral bisphosphonates are significantly less potent than zoledronic acid and require longer treatment courses with less durable responses. 4, 3
Monitoring Treatment Response
Measure serum total ALP at 6-12 weeks after zoledronic acid infusion to assess initial response, with maximum suppression typically occurring at 6 months. 4, 3
For long-term follow-up after zoledronic acid:
- Reassess ALP every 1-2 years if bone turnover normalized 4
- More frequent monitoring (every 6-12 months) is needed with less potent oral bisphosphonates 4
Biochemical relapse (rising ALP) is a more objective indicator for retreatment than symptom recurrence alone. 4
Management of Complications
Bone pain: Bisphosphonates are effective for pagetic bone pain, with zoledronic acid providing the best pain response. 2, 3
Osteoarthritis in joints adjacent to pagetic bone: Bisphosphonate treatment may slow progression, but total hip or knee replacement is recommended when medical management fails. 2, 3
Hearing loss: Bisphosphonates may prevent or slow progression when skull base is involved, though evidence is limited. 3
Spinal cord compression: Bisphosphonates may reverse neurologic deficits from spinal Paget's disease. 3
Fractures: Surgical fixation may be required; preoperative bisphosphonate treatment is recommended to reduce bleeding risk. 3
Key Clinical Pitfalls
Avoid treating asymptomatic patients solely to normalize ALP, as this "treat-to-target" approach lacks evidence for preventing complications and may increase fracture risk. 6, 2
Do not use etidronate, as it inhibits bone formation and has failed to prevent bone loss or fractures in Paget's disease. 8
Ensure adequate renal function before zoledronic acid administration (creatinine clearance >35 mL/min preferred). 8
Monitor for hypocalcemia in the first 2 weeks after zoledronic acid, especially in patients with vitamin D deficiency. 3